HCI-012 breast cancer PDX

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Research area: Breast Cancer
• Description: Human breast cancer patient-derived xenograft (PDX) model that retains high fidelity to original tumour, including spatial structure, intratumour heterogeneity, genomic features, tumour growth rate, metastatic patterns, and drug responses. These highly translatable PDX models can be used to more accurately assess therapeutic efficacy and predict patient responses in preclinical drug validation studies than traditional models. This panel of PDX models includes some of the deadliest forms of breast cancer such as drug-resistant, metastatic tumours, and endocrine-resistant estrogen receptor-positive (ER+) and human epidermal growth factor receptor positive (HER2+) tumours. Sample collected in 2009 from pleural effusion of Caucasian female, age 51 at time of collection with a primary diagnosis of IDC; 2000; recurrences in 2007 and 2008. Patient was a smoker for 14 years, and experienced clinical metastasis to the lymph node and pericardium. Patient had undergone radiation therapy to neck and lung (2009) and had systemic treatment of nab-paclitaxel; 5-fluorouracil; cyclophosphamide; aldesleukin/proleukin; interleukin 2; epirubicin, leucovarin, methotrexate; letrozole (2006 - 2009); doxorubicin (2009); capecitabine (2009), trastuzumab, vinerolbine (2009), capecitibine and lapatinab (2009) prior to sample collection. Patient characteristics were as follows - ER status: negative, PR status: negative, HER2 status: primary tumour was positive and amplified; PE not tested. PDX characteristics were as follows - ER status: negative, PR status: negative, HER2 status: positive, mixed. PDX information: PAM50 subtype is luminal B/HER2-enriched, PTEN negative by IHC, and shows metastasis to lung, thyumus, ovary, kidney, liver and lymph node.

Patient Details

• Cancer: Breast cancer
• Cancer subtype: Infiltrating Ductal Carcinoma
• Cancer stage grade: Stage IV
• Biopsy site: Pleural Effusion Fluid
• Gender: Female
• Patient ethnicity: Caucasian
• Treatment history: Pretreated: Patient had undergone radiation therapy to neck and lung (2009) and had systemic treatment of nab-paclitaxel; 5-fluorouracil; cyclophosphamide; aldesleukin/proleukin; interleukin 2; epirubicin, leucovarin, methotrexate; letrozole (2006 - 2009); doxorubicin (2009); capecitabine (2009), trastuzumab, vinerolbine (2009), capecitibine and lapatinab (2009) prior to sample collection

Engraftment Details

• Mice passaged: Yes
• Engraftment site: Cleared mammary fat pad
• Sample type: Suspension in Matrigel
• Host strain: Immunocompromised mice NOD scid gamma (NSG) Jackson Laboratory 5557; NOD/scid, Jackson Laboratory 1303 or NOD rag gamma (NRG), Jackson Laboratory 7799
• Histology: PAM50 subtype Luminal A Her2 enriched
• Production details: Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation.

Handling

• Initial handling information: Implant into the cleared inguinal mammary fat pad of female Immune-compromised mice (NOD.SCID) and NGS. Time to grow to 2cm: 4 months (both)
• Additional notes: Additional Information on PDX establishment: https://www.nature.com/articles/s43018-022-00337-6/figures/9

Application Details

• Genetic data: Whole exome sequencing, SNP array, CNV data and RNA sequence from Guillen et al. 2022 Nature Cancer, is available in NIH database dbGaP under accession number phs002479.v1.p1

References

• Tufail, et al. 2024. Journal of Translational Med. Jan 3:22(1):15. PMID: 38172946
• Bhattacharya, et al. 2023. Journal of Experimental & Clinical Cancer Research. Dec 16:42(1):343. PMID: 38102637
• Prekovic, et al. 2023. EMBO Molecular Medicine. Dec 7:15(12):e17737. PMID: 37902007
• Daneshdoust, et al. 2023. Cells. Sep 30:12(19):2338. PMID: 37830602
• Wang, et al. 2023. Cell Bioscience. Dec 1:13(1):224. PMID: 38041134
• Guillen, et al. 2022. Nature Cancer. Feb 3(2):232-250. PMID: 35221336